- Global Pharma News & Resources

[2021] U.S. Meibomian Gland Dysfunction Market Is Expected to Exhibit a Strong 15.4% CAGR By 2030 – Coherent Market Insights

SEATTLE, April 29, 2021, (PHARMIWEB) — U.S. Meibomian Gland Dysfunction Market Analysis

Impact of COVID-19 epidemic

The most recent outbreak of SARS-CoV-2 virus was first reported in Wuhan City of China on December 31, 2019. On March 11, 2020, the World Health Organization (WHO) had declared COVID-19 virus as a global pandemic.

As per the World Health Organization’s report, a total of 6.61 million infections as a result of COVID-19 were recorded as of September, 2020 worldwide.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report@

COVID-19 pandemic has majorly impacted the economy in three different ways; with its direct effect on manufacture and demand by creating disturbances in the supply chain, with its financial influence on the financial markets and firms. As per the newest update from Economic Times, there is decline in spending by consumers as they remained indoor and avoided travelling, shopping or any congregation in public which has led to a drop of 32% annual rate in the second quarter of 2020 in the U.S.

Moreover, companies contributing in the U.S. meibomian gland dysfunction market have been facing several issues on different fronts as a result of COVID-19 epidemic. These issues are distribution of raw materials for producing formulation of drugs due to unevenness in transportation services. Furthermore, suppliers of drug products are witnessing an uneven demand from the retailers.


The dry eye syndrome (DES) usually leads to meibomian gland dysfunction, which is also called as keratoconjunctivitis sicca or keratisis sicca. Generally, patients suffering for DES experience a damage in their ocular surface, tear layer becomes unstable, and disruptions in sight. This tear film covers the ocular surface which is comprised of three inter-twined layers, a lipid layer which is superficial and is produced from meibomian glands that aid in minimizing evaporation of tears and equal distribution of tear. The thick central aqueous layer is produced by lacrimal gland and the innermost hydrophilic mucin layer is produced by goblet cells of conjunctiva and epithelium of ocular surface.

The U.S. meibomian gland dysfunction market is expected to manifest a CAGR of 15.4% over the forecast period of 2020-2030 and is estimated to worth around US$ 1,976.6 million in 2020.

Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @


Rising incidences of meibomian gland dysfunction syndrome are expected to propel growth of the U.S. meibomian gland dysfunction market over the forecast period.

As per the American College of Surgeons’ Fellow, meibomian gland disease or evaporative dry eye, is the most common cause of dry eye globally. An estimated 50 to 70% of elderly population has some degree of dry eye and almost 70% of this cases have minimum some instances of meibomian gland disease.

In 2017, as per the publication of American Optometric Association, over 16 million of American population with majority of women, were affected with dry eye disease, and around 70% of patients among this population had meibomian gland disease.

Moreover, the specific medications such as decongestants, blood pressure medications, antihistamines, and antidepressants have the potential to minimize the production of tear which leads to dry eye symptoms, hence, causing meibomian gland dysfunction.

Increasing usage of smartphones and computers is expected to enhance the prevalence of U.S. meibomian gland dysfunction market.

Frequent use of video-screens and computers among the population, increases the risk of developing meibomian gland dysfunction as excessive use of these screens can result in decline of blinking and production of tears. Usage of digital devices has remarkably increased recently among all age-groups considering the rise in popularity of social media and online streaming services.

The digital screens emit blue light which may result in some symptoms of dry eyes that are responsible for causing meibomian gland dysfunction. Prolonged exposure to this blue light which is in the range of 400-500 nm, can be hazardous to the retina. Even the light exposure with less intensity for longer period of time can induce a photo-chemical damage to the eyes.

Moreover, excessive stress and lack of sleep can play a vital role in the creation of dry eye syndrome as a result of oily tear gland dysfunction.

As per the report from the Centers for Disease Control and Prevention in 2017, over 40 million workers in the U.S. get less than six hours of sleep each night.

View Press Release For More Information @

Market Taxonomy   

According to the type of drug: Antibacterial eye drops, Cyclosporine, Omega-3 supplements, AZR MD 001, Steroids, TP 03, NOV03 (Novatears), and HY02 – Minocycline.

According to the Route of Administration: Oral, Topical.

According to the Distribution Channel: Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies.


Possible side-effects of drugs such as steroids that are used for treating meibomian gland dysfunction syndrome have variety of side-effects on patient’s body who is taking the dosage in excess for a longer period of time. This factor is expected to limit growth of the U.S. meibomian gland dysfunction market over the forecast period.

Complicated diagnosis of this disease is expected to hinder the U.S. meibomian gland dysfunction market over the forecast period. Due to absence of any test for diagnosing meibomian gland dysfunction, the healthcare providers use slit lamp findings such as tear meniscus height, lid observations, and corneal staining for assessing the disease. Other tests such as inflammatory markers, tear film osmolarity, and conjunctival staining are not used commonly due to their higher costs and time-consuming process. Furthermore, there are variations between symptoms and their results after the tests for meibomian gland dysfunction as they are not related to each other. This variance can create confusion among healthcare providers and patients.

Key Players

Key companies contributing in the U.S. meibomian gland dysfunction market include I-MED Pharma Inc., Sentiss Pharma Pvt. Ltd., Santen Pharmaceutical Co., Ltd., and Akorn, Inc., RegeneRx, Bausch Health Companies Inc., are Pfizer, Inc., AbbVie Inc., Novartis AG, OASIS Medical, Johnson and Johnson, and Vision Care Inc.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website –


Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 29-Apr-2021